Q-omics provides the consensus-scored PHACTR2 profile across patient tissues and cancer cell-line models. PHACTR2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PHACTR2 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, PHACTR2 protein abundance shows 22,135 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where PHACTR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHACTR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHACTR2 survival associations across molecular data types. PHACTR2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHACTR2 RNA expression–survival associations across cancer types. High PHACTR2 expression shows unfavorable associations in BLCA, LIHC and OV, but favorable associations in KIRC, ACC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PHACTR2 RNA expression.
This table summarizes PHACTR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PHACTR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHACTR2 shows lower tumor expression in LUAD, LUSC, KICH, THCA, UCEC and BRCA. The LUAD box plot shows higher PHACTR2 RNA expression in normal versus tumor tissue (log2 FC = −1.526, t-test p < 0.001).
This table shows molecular features associated with PHACTR2 in patient tissues and cancer cell lines. In patient samples, PHACTR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHACTR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
